SM
SCPH

Sabby Management’s scPharmaceuticals SCPH Stock Holding History

Sabby Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-42,407
Closed -$316K – 142
2020
Q3 		$316K Sell
42,407
-83,345
-66% -$651K 0.05% 92
2020
Q2 		$926K Buy
+125,752
New +$1.1M 0.19% 49

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Sabby Management's SCPH Position: Q4 2020 in Review

Sabby Management sold out of scPharmaceuticals (SCPH) in Q4 2020, closing a stake of 42,407 shares — an estimated $316K sold.

Sabby Management first reported a position in SCPH in Q2 2020 and held it in 2 quarters. The position peaked at $926K in Q2 2020. 47 funds tracked by Wall St. Rank hold SCPH as of Q4 2020.

  • Sabby Management reported no remaining scPharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Sabby Management sold 42,407 scPharmaceuticals shares in Q4 2020, an estimated $316K.
  • Sabby Management first reported a position in scPharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Sabby Management's scPharmaceuticals position peaked at $926K in Q2 2020.
  • 47 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.